Esperion (ESPR) Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock in the proposed offering are to be sold by Esperion. Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the proposed offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- No jobs report amid shutdown, Apple pulls ICEBlock from App Store: Morning Buzz
- Esperion’s Strategic Legal Settlements and Regulatory Advancements Drive Buy Rating
- Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s
- Esperion management to meet with Cantor Fitzgerald
- Esperion price target raised to $9 from $7 at Cantor Fitzgerald